New iOS-approved insulin system aims to cut daily decision load for workers with type 1 diabetes
Health Canada has cleared the mylife Loop system for use with iOS and Abbott’s FreeStyle Libre 3 Plus sensor, widening automated insulin delivery options for Canadians with type 1 diabetes.
Health Canada’s decision extends compatibility for mylife Loop, which links the mylife YpsoPump insulin pump with the mylife CamAPS FX app and algorithm from CamDiab Ltd and compatible glucose monitoring systems.
The system uses adaptive, smartphone-based automated insulin delivery (AID) to help manage insulin dosing and other therapy-related decisions in daily life.
Managing type 1 diabetes involves frequent health-related decisions, including glucose monitoring, insulin dosing, nutrition and activity planning.
In Europe, where mylife Loop has been available for more than three years, patient-reported experience data indicate an effect on day-to-day management.
In the dQ&A survey, users rated mylife Loop number one for reducing the perceived mental load associated with diabetes management.
Karina Schneider, general manager of Ypsomed Canada, said people with type 1 diabetes face “countless decisions” in daily therapy and that expanding mylife Loop compatibility reduces that burden and gives them more flexibility in managing their condition.
mylife Loop’s expanded approval follows ongoing collaboration between mylife Diabetes Care, CamDiab and Abbott to address the needs of patients and healthcare professionals.
Commercial availability will depend on launch timing and local market conditions.
The approval comes less than a year after mylife Loop launched in Canada on Android in March 2025 as the first smartphone‑based AID system available on the domestic market.
Since launch, use has grown among people living with type 1 diabetes and among healthcare professionals.
